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Abstract
The fundamental idea and the effects of heat on cancer
cells are well known. However, the results obtained in
therapy by hyperthermia (HT) alone have been only
partially satisfactory. Treatment at temperatures between
40 and 44°C is cytotoxic for cells in an environment with a
low oxygen partial pressure and low pH, conditions that
are found specifically within tumour tissue, due to
insufficient blood perfusion. Under such conditions
radiotherapy is less effective, and systemically applied
cytotoxic agents will reach such areas in lower
concentrations than in well-perfused areas. Therefore,
clinically, it is preferred to use hyperthermia in
combination with radiation therapy and chemotherapy.
Hyperthermia can be applied by several methods: local
hyperthermia by external or internal energy sources;
regional hyperthermia by perfusion of organs or limbs, or
by irrigation of body cavities; and whole-body
hyperthermia. Number of studies have reported the
combination of thermo-radiotherapy. Consequently,
much attention has been focussed on identifying agents
among the conventional chemotherapeutic substances
that can sensitise tumour cells to hyperthermia-induced
damage with minimal effects on normal cells. In this
review, we overviewed important mechanisms of
hyperthermia-induced apoptosis and the substances
which can act as heat sensitisers in cancer therapy.
Keywords: Hyperthermia, Apoptosis, Heat sensitizer.
Introduction
“Those who cannot be cured by medicine can be cured by
surgery. Those who cannot be cured by surgery can be
cured by fire [hyperthermia]. Those who cannot be cured
by fire, they are indeed incurable”.—Hippocrates (479–377)
The use of elevated temperature, hyperthermia (HT) is not a
new treatment for cancer. Hippocrates was aware of the
potential of heat to cure or shrink tumours. Tumour
shrinkage after a high fever due to an infection was reported
in 1866.1 Heat has profound effects on cells. At low doses,
heat enhances recovery from injury. At high doses, it leads to
cell death that may be immediate for extreme doses. The role
of HT alone as a cancer treatment is limited. It has been
recognised as an effective and useful tool, especially in
combination with conventional therapies to halt tumour
growth. The significant advantage to this type of
combination therapy is the possibility of using lower doses of
chemotherapy and radiation leading to more effective
treatment with fewer unwanted side effects, and a reduced
resistance of cancer cells to the combination of drug and
radiation. Numerous clinical trials have studied hyperthermia
in combination with conventional therapies. Many of these
studies, but not all, have shown a significant reduction in
tumour size when hyperthermia is combined with other
treatments.2 Temperature between 41°C-44°C is not toxic to
the normal cells, but show toxicity in cancerous cells.
In the clinical application of HT, three methods can be
employed: local, regional and whole-body HT. The choice
of the method to use on any given patient depends on the
type of the cancer, its location and its stage. Special
thermometres are used to monitor the temperature
during the course of the treatment.
Local HT is used to treat localised cancers. It can be
applied by external, intraluminal and interstitial methods
to treat tumours on the skin or just underneath it,
tumours within or near the body cavities, and to treat
deep tumours within the body, such as brain tumour.
Different types of energy sources may be used to apply
heat such as microwave, radiofrequency and ultrasound.3
Regional HT is used to heat large areas of tissue such as
body cavity, organ or limb. Different methods can be
employed depending on the type of cancer. For example,
deep tissue regional HT is applied for cancers within the
body like bladder4 or cervix; regional perfusion technique is
applied for the cancers of arm and legs such as melanoma
or cancers of some organs like liver or lung; peritoneal
perfusion technique is applied for the treatment of cancers
within the peritoneal cavity, including primary peritoneal
mesothelioma and stomach cancer.3
Whole-body HT is used to treat metastatic cancers. A
common characteristic is that energy is introduced into
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the body while at the same time energy losses are
minimised. Most recent heat induction methods used are
irradiation with infrared, radiofrequency and microwave
electromagnetic energy. These techniques can be applied
solely or in combination.3
Normal tissue toxicity will result directly from hyperthermia
when the tolerance limits are exceeded. Experimental studies
have shown that most normal tissues are not damaged when
the temperature over 1 hour of treatment does not exceed
44°C. The toxicity from superficial hyperthermia is usually a
skin burn, heals with conservative treatment. Subcutaneous
fat burns were seen in 3%-12% of the patients treated with
deep hyperthermia. It does not usually cause much
discomfort to the patient who feels a subcutaneous lump,
which is tender for a few days to a maximum of a few weeks
and then disappears spontaneously. Toxicity from whole-
body hyperthermia depends on, besides temperature, the
patient’s general condition, condition of organ systems and
the physiological conditions during the treatment. During
any application of hyperthermia, it is important to avoid
pressure sites, since hypoxic normal tissues will be more
sensitive to hyperthermia.3
HT is known as a potent radio-sensitiser and there are many
studies which deal with the biochemical and biophysical
mechanisms leading to cell death from HT or from a
combination of HT and ionising radiation. Studies are also
available on the combination of HT and drugs-induced
apoptosis. In this review, we will discuss the factors and
mechanisms which make combination of HT with drugs
and radiation an effective tool for cancer therapy.
Cellular physiological changes induced by HT
Hyperthermia induces numerous changes in cellular
physiology (Table-1). These cellular alterations make a
combination of heat with drugs and radiation very
effective. Below some important cellular responses to
potential therapeutic regimens are discussed in detail:
Alteration in membrane permeability
Membranes are known to be extremely sensitive to heat
stress because of their complex molecular composition of
lipids and proteins. At a certain temperature, lipids
change from a tightly packed gel phase to a less tightly
packed crystalline phase, and permeability of the cell
membrane (membrane fluidity) increases. Hyperthermia-
induced cell membrane permeability leads to increased
drug delivery into tumour cells. In addition, increased
vascular permeability due to heat increases in endothelial
gap size also aids drug delivery into the tumours.
Alteration in membrane permeability also alters the
cellular content of several ions (Na+, Mg2+, K+) in a number
of cells, although the changes in these ion balances are
not primarily responsible for hyperthermic cell death.5
Another ion which might be involved in hyperthermic cell
death is Ca2+. Influxes of extracellular Ca2+ stimulate the
activity of calmodulin-dependent protein kinases, inositol
triphosphate production and other signalling cascades.6
Modification of cytoskeletal system
The response of cytoskeletal systems to HT varies
depending on the cell type and HT dose.7 Hyperthermia-
induced disassembly of the cytoskeleton, enlarges the
tumour pores which enables easier drug delivery.7 It also
induces alteration of the mitotic spindles,7 centrosome
organisation, and protein denaturation which results in
the formation of multinucleated non-clonogenic cells.8
Furthermore, it also induces alterations of integrin-
cytoskeleton network with concomitant cell shape
change, anoikis and programmed cell death.9
Inhibition of DNA repair
Dioxyribonucleic acid (DNA) appears to be the primary target
for most of the currently adopted chemotherapeutic drugs and
radiation.10 The main obstacle for cancer treatment is the
resistance of cells to the cytotoxic effects of drugs and radiation.
Several possible mechanisms have been suggested to account
for this resistance, for example, intrinsic DNA repair capabilities,
vascular insufficiency, and cellular impermeability.11
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Table-1: Molecular effectors of hyperthermia.35
Cellular components
Functional alterations
Cell membrane Alterations in fluidity/ stability 
Changes in structure
Impairment of ion transport (Ca2+, Na+, Mg+, K+)
Modification in membrane potential
Modulation of the transmembrane efflux pump 
Cytoplasm Denaturation of protein structure and function
Impairment of protein synthesis
Aggregation of proteins 
Induction of HSP synthesis
Mitochondria Amplification of mitochondrial inner membrane permeability.
Depolarization of mitochondrial membrane potential 
Reduction of ATP production
Generation of reactive oxygen species (ROS)
Disruption of Ca2+ transport across mitochondrial membrane.
Endoplasmic
Reticulum (ER) ER stress due to excessive accumulation of misfolded proteins.
Nucleus Impairment of RNA/DNA synthesis
Inhibition of DNA repair enzymes
Alteration of DNA conformation
Modification of gene expression and signal transduction.
RNA: Ribonucleic acid.
DNA: Dioxyribonucleic acid.
Hyperthermia is reported to induce DNA double-strand breaks
due to the denaturation and dysfunction of heat-labile repair
proteins such as DNA polymerases12 or to the precipitation of
denatured proteins onto nuclear chromatin structures,
generating a barrier which prevents repair enzymes from
reaching damage sites.13 HT-induced protein denaturation is
also reported to alter multiple nuclear matrix-dependent
functions [e.g., DNA replication, DNA transcription, Messengar
ribonucleic acid (mRNA) processing and DNA repair].14
It is thus hypothesised that hyperthermia treatment sensitises
tumour cells to chemotherapeutic drugs or radiation by
altering cytoskeleton re-organisation, enhancing membrane
permeability and inhibiting DNA repair.15
HT-induced signalling pathways
Pro-apoptotic signaling pathways
Apoptosis is a genetically programmed and biochemically
active mode of cell death in which the cell actively
participates in its own destruction.16 It is required for cell life
span regulation and normal development.15 Apoptosis also
aids in the self-deletion of injured cells, terminal
differentiation of epithelial cells, and organ and tissue
shaping.16 Abnormalities in this process are implicated in
several human diseases, including cancer. Radiation, cytotoxic
drugs, viruses and hyperthermia can trigger this process.
Hyperthermia within a temperature range of 41-45ºC
induces apoptosis to varying degrees in many cell lines.17 It
induces apoptosis mainly through reactive oxygen species
(ROS) generation, and a likely source of elevated ROS
production is the mitochondria.17Mitochondria are believed
to produce basal levels of ROS in the form of single-electron
leakage to oxygen during normal metabolism.18 This can
increase dramatically under conditions in which the
mitochondria are damaged or exposed to certain toxic
conditions.17 In addition, HT can also alter the expression of
the Bax and Bcl-2 genes, where such changes are dependent
on the sensitivity of cell lines to HT.19 In thermo-resistant cell
lines, HT by itself cannot change the expression of Bax and
Bcl-2, but the combination of HT and chemotherapy or
radiotherapy can up-regulate Bax and down-regulate Bcl-2
expression.20 Furthermore, hyperthermia-induced increase
in intracellular Ca2+ ion ([Ca2+]i) concentration is also thought
to be involved in cell death. However, evidence for the role of
[Ca2+]i in hyperthermic cell death is contradictory. Some
investigators have stated that HT-induced increase in Ca2+
does not play a key role,21while others have concluded that
thermal perturbations in [Ca2+]i are among the primary
events leading to heat-induced cell killing.22 These
observations suggest that the role of Ca2+ in HT-induced cell
killing may be dependent on cell type. HT is reported to
increase the expression of the receptor inositol
triphosphate23 which may regulate the release of Ca2+.
Generally, Ca2+ can act on multiple targets to trigger
apoptosis.24 Lipid peroxidation due to ROS generation is also
reported to alter Ca2+ distribution25 and to activate a Ca2+-
dependent apoptotic pathway23 (Figure).
Anti-apoptotic signaling pathways
HT is also responsible to activate survival/antiapoptotic
pathways that lead to the development of thermo
tolerance. Signalling factors, such as Akt, p38, extracellular
signal-regulated kinase (ERK) etc play important roles in
anti-apoptosis or cellular proliferation pathways.26 Such
anti-apoptosis and cytoprotective signalling factors are
negative for hyperthermic cancer therapy. Therefore,
targeted inhibition of the anti-apoptotic signalling
pathways is an attractive approach for the development
of hyperthermia-induced chemo-sensitisation.
Heat shock proteins (HSPs)
Heat shock proteins (HSPs) were originally identified as
proteins whose expression was markedly increased by heat
shock.26 HSPs represent a heterogeneous group of
molecular chaperones consisting of at least five sub-groups
with different molecular mass and partially varying
biological function. HSPs are usually divided into small HSPs
Vol. 63, No.4, April 2013
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Figure: Scheme of pro-apoptotic signalling pathways activated by hyperthermia.
(molecular mass <40 kDa), and the HSPs60, HSPs70, HSPs90
and HSPs100 proteins families.26All HSPs families share their
chaperoning function, i.e. they unselectively bind to
hydrophobic protein sequences liberated by denaturation.
Thus they prevent irreversible interaction with neighbour
proteins that would result in a loss of function. Several HSPs
are expressed even in unstressed cells and play important
function in normal cell physiology.26 HSPs synthesis can be
induced within minutes by activation of so-called ‘heat
shock factors’(HSF). In hyperthermia, HSPs are thought to be
involved in the protection of cells against heat damage.
Hyperthermia and drug resistance
Drug resistance represents the major cause of treatment
failure in human malignancies, and can be induced by
different mechanisms, of which the pleitrope multidrug
resistance (MDR), has gained particular interest.27
Hyperthermia is a good candidate to overcome various
modes of drug resistance. A number of phase I and II trials
reported successful treatments of patients with
chemorefractory tumours by adding HT to antineoplastic
chemotherapy.28 On the other hand, moderate heat
exposure has been demonstrated to induce HSP
expression in cultured cells, and elevated levels of
intracellular HSP 70 have been shown to be associated
with thermotolerance which may be linked with different
forms of drug resistance (e.g. MDR), and HT has been
shown to induce various forms of drug resistance, too
(including MDR or the heat-dependant inactivation of the
enzyme topoisomerase II). Reversal of drug resistance has
been particularly shown for platinum compounds at
temperatures >42°C, whereas induction of drug resistance
(alone or in conjunction with thermotolerance and HSP-
accumulation) may appear when lower temperatures are
applied. However, available data on hyperthermia and
drug resistance suggest that the positive effect (reversal of
drug resistance) overweighs the disadvantages (induction
of drug resistance) in clinical practice.29
Hyperthermia-induced radiosensitisation
Hyperthermia and radiation act in a synergistic way. This
synergism induces an increase in cell killing even at lower
temperatures, which is not the case when hyperthermia is
implemented alone.29 It appears most pounced in S-phase
cells that are usually resistant to radiation alone. Hypoxic
cells, as well as, those with impaired nutrient supply and/or
acidic pH have been shown to react very sensitively to the
combined treatment of heat and radiation.30
Hyperthermia-induced chemosensitisation
Synthetic heat sensitisers:
One of the promising approaches to the clinical application of
HT is to combine it with chemotherapy
(‘thermochemotherapy’). Numerous in vitro and in vivo
systems have been used to demonstrate the synergistic effects
of HT when combined with a wide range of chemotherapeutic
agents. The combined treatments have shown increased
success in many tumours.31 The synergistic effects occur due
to the alteration in the pharmacokinetics32 and
pharmacodynamics of drugs,29 increases DNA damage11 and
decreases DNA repair.5,8 It converts some innocuous drugs
into highly toxic agents the so-called ‘heat
sensitisers/thermosensitisers.’ An ideal heat sensitiser would be
non-toxic at normal temperatures, but become toxic at
hyperthermic temperature. There are chemical agents that can
act as heat sensitisers at non-toxic concentrations (Table-2).
Natural heat sensitisers
Natural compounds contain greater characteristics of
high chemical diversity and biochemical specificity than
standard chemical compounds. Several studies have
reported the role of natural compounds in cancer cell
apoptosis.33 However, quercetin is the only bioflavonoid
reported in combination with hyperthermia as an
J Pak Med Assoc
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Table-2: Synthetic compounds as a heat sensitiser.35
Drugs Cell line Concentration/°C Target for apoptosis Maximum Enhancement Ratio
Cisplatin (DNA damaging agent) SW1573 5  M /41-43°C (60min) DNA 7.3 - 7.8 *
Paclitexal (Microtubule stabilizing agent) FM3A 10  M /43°C (60min) Microtubules 2.1 *
Etoposide (VP-16) (DNA damaging agent) LU65A 8  M /43°C (45min) DNA 1.8 *
5-Fluorouracil (Anti-metabolite) CCRF-CEM 100  M / 42°C (120min) DNA and RNA 1.0 *
Verapamil (Ca2+ Channel blocker) U937 100  M /42-44°C (30min) Mitochondria 1.9 - 4.1 §
Lidocaine (Local anesthetic) U937 1 mM /44°C (10min) Mitochondria 3.6 §
6-Formylpterin (Intracellular hydrogen peroxide generator) U937 300  M /44°C (20min) Mitochondria 4.4 §
Furan-fused tetracyclic compounds (Anti-viral agent) U937 20  M /44°C (20min) Mitochondria 6.6 §
Macrosphelides (Anti-metastatic agent) U937 5  M /41°C (20min) Mitochondria 2.1 §
Anisomycin (Protein synthesis inhibitor) U937 0.1 mM/ 41°C (60min) Proteins 1.5 §
DNA: Dioxyribonucleic acid. *Maximum enhancement ratio = Cell death (%) (measured with different methods) in the presence of the drug at elevated temperature / Cell death (%) in the presence of drug at a normal
temperature (37°C). § Maximum enhancement ratio= DNA fragmentation (%) in the presence of a drug at elevated temperatures / DNA fragmentation (%) in the presence of a drug at a normal temperature (37°C).
inhibitor of HSP 70.34 Numbers of medicinal plants are
present which can be studied with HT in order to identify
effective heat sensitisers for cancer therapy.
Conclusion
The clinical application of HT has a strong biological rationale.
Still research is going on to overcome the technical problems
associated with this therapy. Resistance to conventional anti-
cancer drugs creates a dire need to apply alternative
strategies like HT in treating cancers. Furthermore,
combination of HT with available chemotherapeutic agents
or with novel candidates from natural source might open new
dimensions in targeting resistant cancers. Further elucidation
of the molecular mechanisms responsible for the
enhancement of heat-induced apoptotic cell death may
provide a strong basis for the effective use of HT and HT-
induced apoptosis sensitisers in cancer therapy.
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